The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Peptide CDMO Market Research Report 2025
Synopsis
Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis.
A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing.
CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
The global Peptide CDMO market was valued at US$ 3173.9 million in 2023 and is anticipated to reach US$ 8611.6 million by 2030, witnessing a CAGR of 15.0% during the forecast period 2024-2030.
Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively. In terms of product categories, it is divided into APIs and intermediates and FDF, with the former holding the major market share of 67%. In terms of application, commercial is the top application area with a market share of 76%, followed by academic research institutions.
This report aims to provide a comprehensive presentation of the global market for Peptide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide CDMO.
Report Scope
The Peptide CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Segment by Type
APIs and Intermediates
FDF
Segment by Application
Commercial
Academic Research
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis.
A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing.
CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
The global Peptide CDMO market was valued at US$ 3173.9 million in 2023 and is anticipated to reach US$ 8611.6 million by 2030, witnessing a CAGR of 15.0% during the forecast period 2024-2030.
Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively. In terms of product categories, it is divided into APIs and intermediates and FDF, with the former holding the major market share of 67%. In terms of application, commercial is the top application area with a market share of 76%, followed by academic research institutions.
This report aims to provide a comprehensive presentation of the global market for Peptide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide CDMO.
Report Scope
The Peptide CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Segment by Type
APIs and Intermediates
FDF
Segment by Application
Commercial
Academic Research
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 Market by Application
1.3.1 Global Peptide CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Commercial
1.3.3 Academic Research
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide CDMO Market Perspective (2019-2030)
2.2 Peptide CDMO Growth Trends by Region
2.2.1 Global Peptide CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Peptide CDMO Historic Market Size by Region (2019-2024)
2.2.3 Peptide CDMO Forecasted Market Size by Region (2025-2030)
2.3 Peptide CDMO Market Dynamics
2.3.1 Peptide CDMO Industry Trends
2.3.2 Peptide CDMO Market Drivers
2.3.3 Peptide CDMO Market Challenges
2.3.4 Peptide CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide CDMO Players by Revenue
3.1.1 Global Top Peptide CDMO Players by Revenue (2019-2024)
3.1.2 Global Peptide CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Peptide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide CDMO Revenue
3.4 Global Peptide CDMO Market Concentration Ratio
3.4.1 Global Peptide CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide CDMO Revenue in 2023
3.5 Peptide CDMO Key Players Head office and Area Served
3.6 Key Players Peptide CDMO Product Solution and Service
3.7 Date of Enter into Peptide CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide CDMO Breakdown Data by Type
4.1 Global Peptide CDMO Historic Market Size by Type (2019-2024)
4.2 Global Peptide CDMO Forecasted Market Size by Type (2025-2030)
5 Peptide CDMO Breakdown Data by Application
5.1 Global Peptide CDMO Historic Market Size by Application (2019-2024)
5.2 Global Peptide CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Peptide CDMO Market Size (2019-2030)
6.2 North America Peptide CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Peptide CDMO Market Size by Country (2019-2024)
6.4 North America Peptide CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide CDMO Market Size (2019-2030)
7.2 Europe Peptide CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Peptide CDMO Market Size by Country (2019-2024)
7.4 Europe Peptide CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide CDMO Market Size (2019-2030)
8.2 Asia-Pacific Peptide CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Peptide CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Peptide CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide CDMO Market Size (2019-2030)
9.2 Latin America Peptide CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Peptide CDMO Market Size by Country (2019-2024)
9.4 Latin America Peptide CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide CDMO Market Size (2019-2030)
10.2 Middle East & Africa Peptide CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Peptide CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Peptide CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Detail
11.1.2 Bachem Business Overview
11.1.3 Bachem Peptide CDMO Introduction
11.1.4 Bachem Revenue in Peptide CDMO Business (2019-2024)
11.1.5 Bachem Recent Development
11.2 PolyPeptide
11.2.1 PolyPeptide Company Detail
11.2.2 PolyPeptide Business Overview
11.2.3 PolyPeptide Peptide CDMO Introduction
11.2.4 PolyPeptide Revenue in Peptide CDMO Business (2019-2024)
11.2.5 PolyPeptide Recent Development
11.3 CordenPharma
11.3.1 CordenPharma Company Detail
11.3.2 CordenPharma Business Overview
11.3.3 CordenPharma Peptide CDMO Introduction
11.3.4 CordenPharma Revenue in Peptide CDMO Business (2019-2024)
11.3.5 CordenPharma Recent Development
11.4 AmbioPharm
11.4.1 AmbioPharm Company Detail
11.4.2 AmbioPharm Business Overview
11.4.3 AmbioPharm Peptide CDMO Introduction
11.4.4 AmbioPharm Revenue in Peptide CDMO Business (2019-2024)
11.4.5 AmbioPharm Recent Development
11.5 USV Peptides
11.5.1 USV Peptides Company Detail
11.5.2 USV Peptides Business Overview
11.5.3 USV Peptides Peptide CDMO Introduction
11.5.4 USV Peptides Revenue in Peptide CDMO Business (2019-2024)
11.5.5 USV Peptides Recent Development
11.6 Thermofischer
11.6.1 Thermofischer Company Detail
11.6.2 Thermofischer Business Overview
11.6.3 Thermofischer Peptide CDMO Introduction
11.6.4 Thermofischer Revenue in Peptide CDMO Business (2019-2024)
11.6.5 Thermofischer Recent Development
11.7 Bio Basic
11.7.1 Bio Basic Company Detail
11.7.2 Bio Basic Business Overview
11.7.3 Bio Basic Peptide CDMO Introduction
11.7.4 Bio Basic Revenue in Peptide CDMO Business (2019-2024)
11.7.5 Bio Basic Recent Development
11.8 JPT
11.8.1 JPT Company Detail
11.8.2 JPT Business Overview
11.8.3 JPT Peptide CDMO Introduction
11.8.4 JPT Revenue in Peptide CDMO Business (2019-2024)
11.8.5 JPT Recent Development
11.9 Genscript
11.9.1 Genscript Company Detail
11.9.2 Genscript Business Overview
11.9.3 Genscript Peptide CDMO Introduction
11.9.4 Genscript Revenue in Peptide CDMO Business (2019-2024)
11.9.5 Genscript Recent Development
11.10 Xinbang Pharma
11.10.1 Xinbang Pharma Company Detail
11.10.2 Xinbang Pharma Business Overview
11.10.3 Xinbang Pharma Peptide CDMO Introduction
11.10.4 Xinbang Pharma Revenue in Peptide CDMO Business (2019-2024)
11.10.5 Xinbang Pharma Recent Development
11.11 ScinoPharm
11.11.1 ScinoPharm Company Detail
11.11.2 ScinoPharm Business Overview
11.11.3 ScinoPharm Peptide CDMO Introduction
11.11.4 ScinoPharm Revenue in Peptide CDMO Business (2019-2024)
11.11.5 ScinoPharm Recent Development
11.12 SN Biopharm
11.12.1 SN Biopharm Company Detail
11.12.2 SN Biopharm Business Overview
11.12.3 SN Biopharm Peptide CDMO Introduction
11.12.4 SN Biopharm Revenue in Peptide CDMO Business (2019-2024)
11.12.5 SN Biopharm Recent Development
11.13 CBL
11.13.1 CBL Company Detail
11.13.2 CBL Business Overview
11.13.3 CBL Peptide CDMO Introduction
11.13.4 CBL Revenue in Peptide CDMO Business (2019-2024)
11.13.5 CBL Recent Development
11.14 Piramal Pharma
11.14.1 Piramal Pharma Company Detail
11.14.2 Piramal Pharma Business Overview
11.14.3 Piramal Pharma Peptide CDMO Introduction
11.14.4 Piramal Pharma Revenue in Peptide CDMO Business (2019-2024)
11.14.5 Piramal Pharma Recent Development
11.15 CPC Scientific
11.15.1 CPC Scientific Company Detail
11.15.2 CPC Scientific Business Overview
11.15.3 CPC Scientific Peptide CDMO Introduction
11.15.4 CPC Scientific Revenue in Peptide CDMO Business (2019-2024)
11.15.5 CPC Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
